Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
Functional Genomic Screening to Identify Essential Regulators of Colorectal Cancer Drug Tolerant Persistor Survival
EF 2025-26
Résumé
Chemotherapy is the main treatment for advanced colorectal cancer (CRC), and while many patients respond at first, the cancer often comes back and becomes resistant, so most patients do not survive beyond five years. Our lab has found that CRC tumor relapse is driven by a small number of cells that survive chemotherapy by temporarily slowing their growth and entering what is known as a drug tolerant persistor (DTP) state. Finding ways to kill DTPs could greatly improve CRC treatment by preventing tumor relapse. My research aims to identify new vulnerabilities in CRC DTPs using genetic screening. By applying a gene-editing technology called CRISPR, I will individually inactivate every gene in the human genome to determine how the loss of each gene affects the survival of CRC DTPs. The genes with the strongest impact on DTP survival will be studied further in mice with CRC. Specifically, we will treat these mice with chemotherapy and then test if inhibiting the candidate genes can prevent their tumors from returning after treatment. These genes can be used as targets for new drugs that could prevent tumour relapse and greatly improve the survival of patients with this deadly disease.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559731
Name
Kleine Nicholas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Functional Genomic Screening to Identify Essential Regulators of Colorectal Cancer Drug Tolerant Persistor Survival
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cancer Signalling; Colorectal Cancer; Crispr Screen; Drug Tolerant Persisters
Abstract
Chemotherapy is the main treatment for advanced colorectal cancer (CRC), and while many patients respond at first, the cancer often comes back and becomes resistant, so most patients do not survive beyond five years. Our lab has found that CRC tumor relapse is driven by a small number of cells that survive chemotherapy by temporarily slowing their growth and entering what is known as a drug tolerant persistor (DTP) state. Finding ways to kill DTPs could greatly improve CRC treatment by preventing tumor relapse. My research aims to identify new vulnerabilities in CRC DTPs using genetic screening. By applying a gene-editing technology called CRISPR, I will individually inactivate every gene in the human genome to determine how the loss of each gene affects the survival of CRC DTPs. The genes with the strongest impact on DTP survival will be studied further in mice with CRC. Specifically, we will treat these mice with chemotherapy and then test if inhibiting the candidate genes can prevent their tumors from returning after treatment. These genes can be used as targets for new drugs that could prevent tumour relapse and greatly improve the survival of patients with this deadly disease.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kleine, Nicholas
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~